Practice Parameter for the Assessment and Treatment of Children and Adolescents With Substance Use Disorders

 This parameter was developed by Oscar G. Bukstein, M.D., and the Work Group on Quality Issues: William Bernet, M.D., and Oscar G. Bukstein, M.D., Co-Chairs, and Valerie Arnold, M.D., Joseph Beitchman, M.D., Jon Shaw, M.D., R. Scott Benson, M.D., Joan Kinlan, M.D., Jon McClellan, M.D., and Saundra Stock, M.D. AACAP staff: Kristin Kroeger Ptakowski.A group of invited experts also reviewed the parameter. The Work Group on Quality Issues thanks William Arroyo, M.D., Judith Cohen, M.D., Michael A. Dawes, M.D., Deborah Deas, M.D., Mark Godley, Ph.D., Susan Godley, Ph.D., Scott Henggeler, Ph.D., Steven Jaffe, M.D., Yifrah Kaminer, M.D., Howard Liddle, Ph.D., Robert Milan, M.D., Paula D. Riggs, M.D., Cynthia Rowe, Ph.D., Deborah Simkin, M.D., Jose Szapocznik, Ph.D., and Naimah Weinberg, M.D.This parameter was reviewed at the member forum at the 2002 annual meeting of the American Academy of Child and Adolescent Psychiatry.During January to April 2004, a consensus group reviewed and finalized the content of this practice parameter. The consensus group consisted of representatives of relevant AACAP components as well as independent experts: William Bernet, M.D., Chair; Oscar G. Bukstein, M.D., author of the parameter; Saundra Stock, M.D., and Joseph Beitchman, M.D., representatives of the Work Group on Quality Issues; Thomas F. Anders, M.D., representative of the AACAP Council; Steven L. Jaffe, M.D., and Shashi Bhatia, M.D., representatives of the AACAP Assembly of Regional Organizations; Ramon Solhkhah, M.D., chair of the AACAP Committee on Substance Abuse and Addictions; Deborah R. Simkin, M.D., former chair of the AACAP Committee on Substance Abuse and Addictions; and Kristin Kroeger Ptakowski, Director of Clinical Affairs, AACAP.This practice parameter was approved by AACAP Council in June 2004. This practice parameter is available on the Internet (www.aacap.org).Reprint requests to the AACAP Communications Department, 3615 Wisconsin Avenue, N.W., Washington, DC 20016.Disclosure: Dr. Bukstein has received research funding from McNeil Consumer and Specialty Pharmaceuticals, Shire Pharmaceuticals, and Noven Pharmaceuticals; has served as a consultant for McNeil Consumer and Specialty Pharmaceuticals, Shire Pharmaceuticals, and Forest Laboratories; and is on the speaker's bureau for McNeil Consumer and Specialty Pharmaceuticals. Members of the consensus group were asked to identify any conflicts of interest that they may have with respect to their role in reviewing and finalizing the content of this practice parameter. One or more of the consensus group members were on the speaker's bureau for one or more of the following pharmaceutical companies: Abbott, Eli Lilly, GlaxoSmithKline, Janssen, Ortho-McNeil, Pfizer, Shire, and Wyeth.

PII: S0890-8567(09)61641-5

doi:10.1097/01.chi.0000159135.33706.37